Skip to main content
Explore URMC

menu

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

Research Question:
Does the drug BIIB092 help patients with Alzheimer's disease?

Basic Study Information

Purpose:
To evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. To evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD. To evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD.

Location: AD-CARE, University of Rochester

Study Contact Information

Study Coordinator: US Biogen Clinical Trial Center
Phone: (585) 760-6562
Email: clinicaltrials@biogen.com

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search